| DNA replication |
1.81 |
1.77e-1 |
34/36 (94.44%) |
PCNA;MCM4;RPA3;...
|
| p53 signaling pathway |
1.81 |
8.84e-2 |
63/73 (86.3%) |
CCNE2;RRM2;PERP;...
|
| Prostate cancer |
1.79 |
7.62e-2 |
93/97 (95.88%) |
CCNE2;PDGFD;PDGFRA;...
|
| Hedgehog signaling pathway |
1.68 |
1.69e-1 |
43/56 (76.79%) |
GAS1;PRKACB;GSK3B;...
|
| FoxO signaling pathway |
1.65 |
1.81e-1 |
118/131 (90.08%) |
SGK1;CDKN1B;PIK3CD;...
|
| Glyoxylate and dicarboxylate metabolism |
1.64 |
1.61e-1 |
23/30 (76.67%) |
DLD;SHMT1;ACAT1;...
|
| Base excision repair |
1.63 |
1.49e-1 |
29/33 (87.88%) |
PCNA;MBD4;NEIL1;...
|
| IL-17 signaling pathway |
1.62 |
1.57e-1 |
84/94 (89.36%) |
CXCL2;CXCL1;S100A8;...
|
| Cell cycle |
1.61 |
1.43e-1 |
110/124 (88.71%) |
CCNE2;PCNA;CDKN1B;...
|
| Cellular senescence |
1.56 |
1.95e-1 |
139/156 (89.1%) |
CCNE2;CXCL8;PIK3CD;...
|
| Vasopressin-regulated water reabsorption |
1.55 |
1.93e-1 |
40/44 (90.91%) |
AQP3;GNAS;PRKACB;...
|
| Mismatch repair |
1.53 |
2.15e-1 |
22/23 (95.65%) |
PCNA;RPA3
|
| One carbon pool by folate |
1.51 |
2.22e-1 |
15/20 (75%) |
ALDH1L1;SHMT1;MTHFD1;...
|
| Progesterone-mediated oocyte maturation |
1.51 |
2.07e-1 |
75/100 (75%) |
PRKACB;RPS6KA2;PIK3CD;...
|
| Synthesis and degradation of ketone bodies |
1.50 |
2.09e-1 |
9/10 (90%) |
HMGCS1;ACAT1;BDH2;...
|
| MicroRNAs in cancer |
1.47 |
2.70e-1 |
146/310 (47.1%) |
CCNE2;PDGFRA;FSCN1;...
|
| Steroid biosynthesis |
1.47 |
2.59e-1 |
19/20 (95%) |
DHCR24;CYP51A1;LSS;...
|
| Notch signaling pathway |
1.46 |
2.53e-1 |
49/59 (83.05%) |
JAG1;TLE4;KAT2B;...
|
| Signaling pathways regulating pluripotency of stem cell... |
1.45 |
2.57e-1 |
110/143 (76.92%) |
IL6ST;WNT5A;PIK3CD;...
|
| Melanoma |
1.45 |
2.46e-1 |
68/72 (94.44%) |
PDGFD;PDGFRA;PIK3CD;...
|
| Oocyte meiosis |
1.44 |
2.71e-1 |
90/129 (69.77%) |
CCNE2;PRKACB;RPS6KA2;...
|
| Pentose and glucuronate interconversions |
1.43 |
2.77e-1 |
17/34 (50%) |
UGDH;DCXR;UGT2B28;...
|
| NF-kappa B signaling pathway |
1.43 |
2.67e-1 |
90/104 (86.54%) |
CXCL12;CXCL2;CXCL1;...
|
| Citrate cycle (TCA cycle) |
1.42 |
2.57e-1 |
30/30 (100%) |
DLD;SUCLG2;PC;...
|
| Legionellosis |
1.42 |
2.53e-1 |
51/57 (89.47%) |
CXCL2;CXCL1;CXCL8;...
|
| Viral carcinogenesis |
1.42 |
2.55e-1 |
149/203 (73.4%) |
CCNE2;PRKACB;CDKN1B;...
|
| AMPK signaling pathway |
1.41 |
2.48e-1 |
106/120 (88.33%) |
LEPR;PIK3CD;PFKFB3;...
|
| Rheumatoid arthritis |
1.41 |
2.50e-1 |
78/93 (83.87%) |
CXCL12;CXCL2;CXCL1;...
|
| Glycolysis / Gluconeogenesis |
1.40 |
2.48e-1 |
56/67 (83.58%) |
GPI;DLD;ALDOB;...
|
| Starch and sucrose metabolism |
1.38 |
2.82e-1 |
25/36 (69.44%) |
GBE1;GPI;AGL;...
|
| Ribosome |
-1.37 |
2.41e-1 |
113/158 (71.52%) |
RPS6;RPL10L;RPL13;...
|
| Antigen processing and presentation |
-1.37 |
2.44e-1 |
60/78 (76.92%) |
KIR2DL4;TAP1;HLA-DPB1;...
|
| Hepatitis C |
-1.37 |
2.50e-1 |
139/157 (88.54%) |
IKBKE;CLDN5;CHUK;...
|
| ECM-receptor interaction |
-1.38 |
2.51e-1 |
80/88 (90.91%) |
COL4A3;COL4A2;ITGB1;...
|
| Pantothenate and CoA biosynthesis |
-1.38 |
2.49e-1 |
14/21 (66.67%) |
ALDH3A2;DPYD;PPCDC;...
|
| GnRH secretion |
-1.39 |
2.42e-1 |
60/64 (93.75%) |
ARRB1;KRAS;GPER1;...
|
| Circadian rhythm |
-1.40 |
2.42e-1 |
26/31 (83.87%) |
PRKAB1;PRKAG1;NPAS2;...
|
| Synaptic vesicle cycle |
-1.40 |
2.46e-1 |
63/78 (80.77%) |
ATP6V1H;SLC18A1;SLC1A1;...
|
| Hematopoietic cell lineage |
-1.43 |
2.19e-1 |
90/99 (90.91%) |
ITGB3;CSF1R;HLA-DMB;...
|
| Type I diabetes mellitus |
-1.43 |
2.24e-1 |
38/43 (88.37%) |
TNF;CD86;PTPRN2;...
|
| Steroid hormone biosynthesis |
-1.44 |
2.18e-1 |
43/61 (70.49%) |
UGT2A3;AKR1C1;CYP11B1;...
|
| Fatty acid elongation |
-1.44 |
2.27e-1 |
19/27 (70.37%) |
ELOVL4;MECR;HACD3;...
|
| Platelet activation |
-1.45 |
2.17e-1 |
106/124 (85.48%) |
P2RY1;MAPK3;GNA13;...
|
| Vascular smooth muscle contraction |
-1.46 |
2.26e-1 |
113/133 (84.96%) |
KCNMB4;ACTA2;ROCK1;...
|
| Coronavirus disease |
-1.46 |
2.27e-1 |
215/232 (92.67%) |
IFNA16;RPL15;MAPK3;...
|
| Natural killer cell mediated cytotoxicity |
-1.48 |
2.13e-1 |
99/131 (75.57%) |
IFNA16;KIR2DL3;MAPK3;...
|
| Primary immunodeficiency |
-1.48 |
2.26e-1 |
33/38 (86.84%) |
BTK;AICDA;RFXANK;...
|
| Riboflavin metabolism |
-1.50 |
2.02e-1 |
7/8 (87.5%) |
BLVRB;RFK;ACP2;...
|
| Graft-versus-host disease |
-1.51 |
2.11e-1 |
32/42 (76.19%) |
KIR2DL3;HLA-DMB;KIR2DL1;...
|
| Selenocompound metabolism |
-1.52 |
2.04e-1 |
11/17 (64.71%) |
KYAT3;KYAT1;CTH;...
|
| African trypanosomiasis |
-1.53 |
2.06e-1 |
32/37 (86.49%) |
LAMA4;APOL1;MYD88;...
|
| PPAR signaling pathway |
-1.54 |
2.01e-1 |
66/74 (89.19%) |
ACSBG1;ACSL5;ACSL3;...
|
| Nicotine addiction |
-1.55 |
2.00e-1 |
32/40 (80%) |
GABRE;GABRR2;GABRD;...
|
| Allograft rejection |
-1.56 |
2.15e-1 |
32/38 (84.21%) |
TNF;CD86;PRF1;...
|
| Toll-like receptor signaling pathway |
-1.59 |
1.72e-1 |
94/104 (90.38%) |
JUN;FADD;STAT1;...
|
| Arachidonic acid metabolism |
-1.60 |
1.75e-1 |
48/61 (78.69%) |
GGT1;PLA2G5;ALOX12;...
|
| Autoimmune thyroid disease |
-1.65 |
1.43e-1 |
46/53 (86.79%) |
IFNA10;CD28;IL10;...
|
| Histidine metabolism |
-1.67 |
1.45e-1 |
16/22 (72.73%) |
AOC1;ALDH2;ALDH9A1;...
|
| Neuroactive ligand-receptor interaction |
-1.68 |
1.75e-1 |
294/341 (86.22%) |
GRIA4;IAPP;GLRA2;...
|
| Leishmaniasis |
-1.71 |
1.76e-1 |
67/77 (87.01%) |
TLR4;TGFB2;HLA-DPB1;...
|